About us

About Prolight

Prioritisation support creates better patient flow

Prolight Diagnostics is developing a Point-Of-Care (POC) system. POC means that diagnosis is made with a simple blood test with a mobile instrument. Testing takes place close to the patient, in patient care units, such as healthcentres and nursing homes.

With the Prolight Diagnostics POC system, caregivers are able to focus on implementing the right treatment instead of spending critical time waiting for test results from the laboratory. The technology enables testing close to the patient and quick test results.

The ambition is for the test results to be available to doctors within 10 minutes. This means that the right treatment can be implemented quickly. Patients who need prompt and urgent healthcare can be prioritised at an early stage. This creates a better patient flow.

Based on the analysis, the doctor can quickly assess whether a patient, who may be in a healthcentre or emergency department, a nursing home, or an intensive care unit, has had, for example, a heart attack or not. By testing and analysing close to the patient, healthcare resources can save lives when they are prioritised for the right patient.

Prolight Diagnostics was founded in 1999 in Lund by Masoud Khayyami, PhD in Chemistry at Lund University. The goal was to develop a diagnostic test that could quickly determine if a patient had a heart attack, with a Point-Of-Care test. By measuring substances released from the heart into the blood during the acute myocardial infarction phase, rapid diagnosis can be determined. Since then, the development of general Point-Of-Care Testing (POCT) has progressed. Prolight Diagnostics has focused on developing a system for the biomarker Troponin, a marker that measures whether a patient has suffered a heart attack. We have received indications from the market to develop our POC platform to include more biomarkers. Our flexible testing system may, therefore, be modified to be able to measure markers in, for example, cancer, inflammation, stroke, etc. in the future.

Unique innovation

We have developed the POC system with the first biomarker, highly sensitive Troponin. Through our new innovation, the blood sampling tube can be integrated directly into the automated process. The manual stages found in most methods on the market today, such as pipetting, centrifugation and dilution, can thereby be eliminated.

Our goal is to be able to offer a simple, flexible and automated analysis process.

Vision & strategy

Vision

Prolight Diagnostics' POCT system will help healthcare be able to make quick and safe diagnoses, and be able to offer effective healthcare to the right patients. We want to offer our platform to companies with global sales organisations that address relevant POCT segments.

Strategy

Prolight Diagnostics is developing a new, flexible POCT system with the precision of a hospital laboratory so that doctors will be able to make the correct diagnosis, quickly and safely. The ambition is to offer adequate treatment at the point when the patient is examined at a healthcentre, nursing home, or emergency department, for example.

Initially, we have focused on the highly sensitive Troponin biomarker, which sets high precision requirements and has enormous global sales potential. We also want to be open to evaluating requests from the market to include several biomarkers on our platform, if they are strategically and economically advantageous alternatives.

To meet the requests from potential partners to include several biomarkers in our platform, the Board of Directors decided to wait for a development plan from TTP before investing in the third development stage with only highly sensitive Troponin. In order to successfully integrate all individual functions and further develop the existing POC system with multiplex, planning, additional resources, and investments will be required, together with potential industry partners.

Ambition

The ambition is that analyses with Prolight Diagnostics' POC platform will offer the same precision as analyses in central laboratories, but with a significantly shorter analysis time. Our system has the ambition to provide an analysis results after approximately 10 minutes. This can be compared with analyses that are sent to traditional laboratories, where results can take hours, even up to days, before being available to doctors.